Table 2. Outcomes of patients with bone and soft tissue sarcomas who are referred to an early phase clinical trial clinic

	Ν	OS		
		Median (95% CI), m	HR (95% CI)	p-value
Survival calculated from time of primary tumour diagnosis				
Whole cohort	74	74.6 (43.5-105.7)		
ECT	34	NR	1.0	
No ECT	38	66.4 (31.7-101.2)	1.6 (0.81-3.25)	0.17
Survival calculated from time of ECT referral				
Whole cohort	74	12.7 (7.6-17.7)		
ECT	34	23.3 (-)	1.0	
No ECT	38	10.1 (5.14-14.99)	2.8 (1.40-5.53)	0.002

Abbrev. OS, overall survival; CI, confidence interval; m, months, ECT, early phase clinical trials *only calculated for OS, as most 1st progression is before referral to ECT